AGM
CASC

Alpine Global Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Alpine Global Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-21,311
Closed -$121K – 214
2016
Q2 		$121K Buy
+21,311
New +$145K 0.06% 117

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Alpine Global Management's CASC Position: Q3 2016 in Review

Alpine Global Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2016, closing a stake of 21,311 shares — an estimated $121K sold.

Alpine Global Management first reported a position in CASC in Q2 2016 and held it in 1 quarter. The position peaked at $121K in Q2 2016. 76 funds tracked by Wall St. Rank hold CASC as of Q3 2016.

  • Alpine Global Management reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Alpine Global Management sold 21,311 Cascadian Therapeutics, Inc. shares in Q3 2016, an estimated $121K.
  • Alpine Global Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2016 and held it in 1 quarter.
  • Alpine Global Management's Cascadian Therapeutics, Inc. position peaked at $121K in Q2 2016.
  • 76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2016.

Based on Alpine Global Management's 13F filing for Q3 2016, filed 15 Nov 2016.